This compound is the pivaloyloxymethyl ester prodrug of a carbapenem antibiotic, primarily utilized in the development of advanced oral antibiotics for treating bacterial infections resistant to conventional treatments. Upon hydrolysis in vivo, the active form effectively inhibits bacterial cell wall synthesis, acting as a potent agent against a wide range of gram-positive and gram-negative bacteria. It is explored in pharmaceutical research to enhance the efficacy and stability of carbapenem antibiotics, with the ester form specifically designed to improve oral bioavailability, making it suitable for oral formulations. Research continues to optimize its pharmacokinetic properties and minimize side effects for more effective, patient-friendly antibacterial therapies, particularly for community-acquired infections.